GUIDANCE-MIBC: Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy
Case Comprehensive Cancer Center
Summary
This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.
Description
Muscle-invasive bladder cancer is an aggressive form of cancer with a high chance of metastasis at the time of diagnosis. The standard of care treatment for MIBC is neoadjuvant chemotherapy (NAC), followed by radical cystectomy or removal of the entire bladder, and then pelvic lymph node dissection. While NAC improves the overall survival at 5 years, it is associated with significant toxicities and there are many patient who do not benefit from it. Because of this, there is a need for predictive biomarkers to identify participants who can directly go into surgery without undergoing NAC. Recent…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0). * Planned for radical cystectomy with curative intent. * Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any systemic therapy. Must have 2 negative tests within the screening window. * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2. * Adequate organ function as defined by standard laboratory criteria. * Ability to understand and provide written informed consent. Exc…
Interventions
- Diagnostic TestctDNA testing
Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy.
Location
- Cleveland Clinic FoundationCleveland, Ohio